Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target
Synopsis
According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."
Morgan Stanley on Wednesday raised its price target on Arrowhead Pharmaceuticals (ARWR) to $48 from $45 while keeping an ‘Equal Weight’ rating on the shares.
Shares of the company traded 22% higher at the time of writing on Wednesday morning.
According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."
Redemplo is Arrowhead’s first FDA-approved medicine. Its approval marked a milestone as Arrowhead evolves into a commercial-stage pharmaceutical company.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.